Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).
PaperCitations, authors & open-access status
IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 74 citations, 2017 year and closed oa status.
74
Citations
2017
Year
closed
OA Status